Ropivacaine
As of the edition of 20 October 2026, Ropivacaine is a small molecule: marketed, first approved in 1996 (FR); acts on SCN10A, SCN11A and SCN1A and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Naropin
- First approved
- 20 August 1996 (FR)
- Approvals on record
- 15 in 3 regions
- Holder of the most recent approval
- BioQ Pharma; 3 holders in all
- Registered trials
- 557, 75 stopped early
- Disease areas
- Nervous system; Injuries; Bones, joints and muscles; Cancer; Urinary and reproductive; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Ropivacaine.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| SCN1A | Sodium channel protein type 1 subunit alpha | P35498 |
| SCN4A | Sodium channel protein type 4 subunit alpha | P35499 |
| SCN7A | Sodium channel protein type 7 subunit alpha | Q01118 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
| SCN9A | Sodium channel protein type 9 subunit alpha | Q15858 |
| SCN2A | Sodium channel protein type 2 subunit alpha | Q99250 |
| SCN3A | Sodium channel protein type 3 subunit alpha | Q9NY46 |
| SCN11A | Sodium channel protein type 11 subunit alpha | Q9UI33 |
| SCN8A | Sodium channel protein type 8 subunit alpha | Q9UQD0 |
| SCN10A | Sodium channel protein type 10 subunit alpha | Q9Y5Y9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 198 | 112 | 17 | 21 |
| Phase 1 | 22 | 15 | 1 | 4 |
| Phase 2 | 42 | 27 | 5 | 4 |
| Phase 3 | 91 | 51 | 13 | 19 |
| Phase 4 | 204 | 125 | 20 | 27 |
| All trials | 557 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Applicant and Lead sponsor of trials | 1998 to now |
| Fresenius Kabi | Acquired holder | 2013 to now |
| Astra | Originator | 1996 to 2013 |